Lexeo Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Lexeo Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- LXEO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001907108
Board of directors
-
Bernard Davitian · DirectorSince 2023
-
Brenda Cooperstone · DirectorSince 2023
-
Hauwermeiren Timothy Van · DirectorSince 2024
-
Laura Sepp-Lorenzino · DirectorSince 2026
-
Mette Kirstine Agger · DirectorSince 2023
-
Paula H. Cholmondeley · DirectorSince 2023
-
Reinaldo M. Diaz · DirectorSince 2023
-
Richard Nolan Townsend · Director · Chief Executive OfficerSince 2023
-
Steven Altschuler · DirectorSince 2023
-
Tolga Tanguler · DirectorSince 2024
Chief executives
Richard Nolan Townsend
· Chief Executive Officer
Since November 2023
Board connections
4 of this board's directors also sit on 4 other boards.
- via Hauwermeiren Timothy Van
- via Brenda Cooperstone
- via Laura Sepp-Lorenzino
- via Steven Altschuler
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $935,076
- 23 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 1, 2026 | Bhalla Narinder Pal Officer (Chief Medical Officer) | Open-market sale | −22,306 | $4.42 | $98,593 |
| Jul 1, 2026 | Richard Nolan Townsend Director, Officer (Chief Executive Officer) | Open-market sale | −25,947 | $4.48 | $116,243 |
| Jul 1, 2026 | Otero Jose Manuel Officer (Chief Operating Officer) | Open-market sale | −4,666 | $4.48 | $20,904 |
| Jul 1, 2026 | Tamayo Louis Edward Officer (Chief Financial Officer) | Open-market sale | −4,641 | $4.49 | $20,838 |
| Jun 29, 2026 | Bhalla Narinder Pal Officer (Chief Medical Officer) | Grant or award | +55,000 | — | — |
| Jun 29, 2026 | Richard Nolan Townsend Director, Officer (Chief Executive Officer) | Grant or award | +67,000 | — | — |
| Jun 29, 2026 | Otero Jose Manuel Officer (Chief Operating Officer) | Grant or award | +12,060 | — | — |
| Jun 29, 2026 | Tamayo Louis Edward Officer (Chief Financial Officer) | Grant or award | +12,000 | — | — |
| May 18, 2026 | Otero Jose Manuel Officer (Chief Operating Officer) | Open-market sale | −1,302 | $5.07 | $6,601 |
| May 18, 2026 | Richard Nolan Townsend Director, Officer (Chief Executive Officer) | Open-market sale | −3,342 | $5.06 | $16,911 |
| Apr 6, 2026 | Richard Nolan Townsend Director, Officer (Chief Executive Officer) | Open-market sale | −55,000 | $5.69 | $312,950 |
| Mar 13, 2026 | Richard Nolan Townsend Director, Officer (Chief Executive Officer) | Grant or award | +2,623 | $2.64 | $6,925 |
| Mar 13, 2026 | Otero Jose Manuel Officer (Chief Operating Officer) | Grant or award | +5,930 | $2.64 | $15,655 |
| Feb 18, 2026 | Otero Jose Manuel Officer (Chief Operating Officer) | Open-market sale | −3,016 | $6.40 | $19,302 |
| Feb 18, 2026 | Richard Nolan Townsend Director, Officer (Chief Executive Officer) | Open-market sale | −10,173 | $6.38 | $64,904 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.